The once daily tablet is expected to reach US patients in October 2026.
News|Articles|February 13, 2019
Tegsedi for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Author(s)Drew Boxler
Advertisement
Tegsedi (inotersen, Akcea™ Therapeutics)
Indications: Adult Patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Dosage: 284 mg adminstered by subcutaneous injection 1x weekly
Contraindications
- Platelet count less than 100 x 109/L (4, 5.1)
- History of acute glomerulonephritis caused by TEGSEDI
- Patients with a history of a hypersensitivity reaction to TEGSEDI
Advertisement
Related to this article
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
Advertisement
Advertisement
Trending on Drug Topics
1
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
2
FDA Approves AbbVie's Juvmo for Parkinson Disease
3
Tozorakimab Reduces COPD Exacerbations in Phase 3 Trials
4
Early CGMs Results in Better 5-Year Glucose Control in Type 1 Diabetes
5